Trial · NCT06319170
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Olanzapine (Extended-release Formulation) | Cohort 1: Olanzapine (Fast-D) | 39.26 | Geometric Coefficient of Variation 45.10 | nanograms (ng)/milliliter (mL) | |
| Maximum Observed Plasma Concentration (Cmax) of Olanzapine (Extended-release Formulation) | Cohort 2: Olanzapine (To-be-marketed) | 35.62 | Geometric Coefficient of Variation 67.55 | nanograms (ng)/milliliter (mL) | |
| Maximum Observed Plasma Concentration (Cmax) of Olanzapine (Extended-release Formulation) | Cohort 3: Olanzapine (Slow-C) | 29.68 | Geometric Coefficient of Variation 50.13 | nanograms (ng)/milliliter (mL) | |
| Area Under the Plasma Concentration-time Curve From Study Drug Administration to the Last Measurable Concentration (AUC0-t) of Olanzapine (Extended-release Formulation) | Cohort 1: Olanzapine (Fast-D) | 20994.08 | Geometric Coefficient of Variation 33.77 | hours*ng/mL | |
| Area Under the Plasma Concentration-time Curve From Study Drug Administration to the Last Measurable Concentration (AUC0-t) of Olanzapine (Extended-release Formulation) | Cohort 2: Olanzapine (To-be-marketed) | 20185.90 | Geometric Coefficient of Variation 47.35 | hours*ng/mL | |
| Area Under the Plasma Concentration-time Curve From Study Drug Administration to the Last Measurable Concentration (AUC0-t) of Olanzapine (Extended-release Formulation) | Cohort 3: Olanzapine (Slow-C) | 18461.94 | Geometric Coefficient of Variation 35.44 | hours*ng/mL | |
| Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Olanzapine (Extended-release Formulation) | Cohort 1: Olanzapine (Fast-D) | 21703.07 | Geometric Coefficient of Variation 35.06 | hours*ng/mL | |
| Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Olanzapine (Extended-release Formulation) | Cohort 2: Olanzapine (To-be-marketed) | 22146.09 | Geometric Coefficient of Variation 42.77 | hours*ng/mL | |
| Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Olanzapine (Extended-release Formulation) | Cohort 3: Olanzapine (Slow-C) | 19011.66 | Geometric Coefficient of Variation 37.21 | hours*ng/mL | |
| Number of Participants With at Least 1 Treatment-emergent Adverse Event (TEAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations | Cohort 1: Olanzapine (Fast-D) | 9 | Participants | ||
| Number of Participants With at Least 1 Treatment-emergent Adverse Event (TEAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations | Cohort 2: Olanzapine (To-be-marketed) | 12 | Participants | ||
| Number of Participants With at Least 1 Treatment-emergent Adverse Event (TEAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations | Cohort 3: Olanzapine (Slow-C) | 9 | Participants | ||
| Number of Participants With at Least 1 Serious Adverse Event (SAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations | Cohort 1: Olanzapine (Fast-D) | 0 | Participants | ||
| Number of Participants With at Least 1 Serious Adverse Event (SAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations | Cohort 2: Olanzapine (To-be-marketed) | 1 | Participants | ||
| Number of Participants With at Least 1 Serious Adverse Event (SAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations | Cohort 3: Olanzapine (Slow-C) | 0 | Participants | ||
| Cmax of ZYPREXA (Immediate-release Formulation) | ZYPREXA | 11.09 | Geometric Coefficient of Variation 82.89 | ng/mL | |
| AUC0-t of ZYPREXA (Immediate-release Formulation) | ZYPREXA | 264.22 | Geometric Coefficient of Variation 48.14 | hours*ng/mL | |
| Apparent Plasma Terminal Elimination Rate Constant (λz) of ZYPREXA (Immediate-release Formulation) | ZYPREXA | 0.0159 | Standard Deviation 0.00381 | 1/hour |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06319170/results